FDA Approvals, Highlights, and Summaries: Rheumatology

February 24, 2021

Notable approvals

Tremfya (guselkumab) - Indicated for active psoriatic arthritis

Xeljanz (tofacitinib) - Indicated for active polyarticular course juvenile idiopathic arthritis for children aged 2 years and older

Simponi Aria (golimumab) - New indication for active polyarticular course juvenile idiopathic arthritis in children aged 2 years and older; additionally, indication for psoriatic arthritis extended to include patients aged 2 years and older

Ilaris (canakinumab) - Treatment of active Still disease, including adult onset

Taltz (ixekizumab) - New indication for active nonradiographic axial spondyloarthritis with objective signs of inflammation

Cosentyx (secukinumab) - Also approved for nonradiographic axial spondyloarthritis

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: FDA Approvals, Highlights, and Summaries: Rheumatology - Medscape - Feb 24, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

FDA Approvals, Highlights, and Summaries: Rheumatology

Tables

Comments

Email This

Feedback